FY2024 Earnings Estimate for SNDX Issued By HC Wainwright

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a research note issued to investors on Monday, November 18th. HC Wainwright analyst E. White now expects that the company will earn ($3.75) per share for the year, up from their previous forecast of ($3.83). HC Wainwright currently has a "Buy" rating and a $51.00 target price on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.61) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals' Q4 2024 earnings at ($1.11) EPS, FY2025 earnings at ($3.76) EPS and FY2026 earnings at ($2.98) EPS.

SNDX has been the topic of a number of other research reports. Stifel Nicolaus lifted their price objective on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. JPMorgan Chase & Co. decreased their price objective on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Bank of America lifted their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, August 15th. The Goldman Sachs Group increased their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, StockNews.com raised shares of Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $37.18.

Syndax Pharmaceuticals Stock Up 2.0 %

Shares of SNDX stock traded up $0.31 on Wednesday, hitting $16.08. The stock had a trading volume of 369,131 shares, compared to its average volume of 1,147,293. Syndax Pharmaceuticals has a one year low of $14.97 and a one year high of $25.34. The company has a market cap of $1.37 billion, a PE ratio of -4.42 and a beta of 0.92. The business has a 50 day moving average price of $18.76 and a 200 day moving average price of $20.11.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.16 million. During the same quarter last year, the firm earned ($0.73) EPS.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of hedge funds have recently modified their holdings of SNDX. Iron Triangle Partners LP purchased a new position in shares of Syndax Pharmaceuticals during the first quarter worth $23,159,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth $15,165,000. Eventide Asset Management LLC purchased a new position in shares of Syndax Pharmaceuticals during the third quarter worth about $15,150,000. First Turn Management LLC acquired a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at about $13,147,000. Finally, Vanguard Group Inc. grew its position in shares of Syndax Pharmaceuticals by 13.6% during the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company's stock worth $117,262,000 after acquiring an additional 591,631 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).